Additionally, through regression analysis, it explored the changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) in patients with hypertension and diabetes after receiving different numbers of anti-VEGF treatments, as well as the relationship between the number of injections and visual improvement and edema reduction.<h4>Results</h4>Significant improvements in BCVA and CMT were observed following anti-VEGF treatment, most notably after the first injection. The gene discussed is VEGFA; the disease is diabetes mellitus.